Wednesday - February 27, 2019 Bayer increases sales and earnings – leader in agriculture after acquisition Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros / EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros / Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings / Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline / Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start / Positive safety profile of glyphosate unchanged – Bayer vigorously defending itself against lawsuits/ Net income at 1.695 billion euros, impacted by one-time effects / Core earnings per share at 5.94 euros, above expectations / Net financial debt at 35.679 billion euros, significantly better than expected / Bayer confirms 2019 Group outlook and 2022 targets more
Thursday - June 07, 2018 Bayer closes Monsanto acquisition Bayer successfully completed the acquisition of Monsanto on Thursday. Shares in the U.S. company will no longer be traded on the New York Stock Exchange, with Bayer now the sole owner of Monsanto Company. Monsanto shareholders are being paid 128 U.S. dollars per share. J.P. Morgan assisted Bayer with processing the purchase price payment for the largest acquisition in the company’s history. According to the conditional approval from the United States Department of Justice, the integration of Monsanto into Bayer can take place as soon as the divestments to BASF have been completed. This integration process is expected to commence in approximately two months. more
Monday - June 04, 2018 Bayer plans closing of Monsanto acquisition on June 7 Largest acquisition in company history to double size of agriculture business / Leading innovation engine in agriculture with pro forma R&D investment of 2.4 billion euros in 2017 / Transaction anticipated to generate significant value / Bayer strengthens commitment to sustainability and stakeholder engagement / Bayer to remain company name more
Wednesday - April 04, 2018 Bayer hones its brand profile Dynamic, open, personal: From today forward, these attributes will be the new public face of the Bayer brand. As CEO Werner Baumann explained: “Our brand is our most important distinguishing feature. People from all over the world have been placing their trust in Bayer for more than 150 years.” more
Wednesday - February 28, 2018 Bayer: business at prior-year level – on track with strategy Group sales increased by 1.5 percent (Fx & portfolio adj.) to 35.015 billion euros / Another record year for Pharmaceuticals / Weak business development at Consumer Health / Crop Science business down against prior year due to situation in Brazil – measures taking effect / EBITDA before special items level year on year at 9.288 billion euros / Net income raised by 61.9 percent to 7.336 billion euros / Core earnings per share increased by 1.0 percent to 6.74 euros / Covestro deconsolidated – additional cash inflows of 4.7 billion euros / Monsanto acquisition expected to close in second quarter of 2018 / Group outlook for 2018: increase in sales (Fx & portfolio adj.), EBITDA before special items and core earnings per share at prior-year level due to currency effects more
Thursday - October 26, 2017 Bayer: Sales and earnings increased Covestro deconsolidated / Group sales grow by 1.2 percent (Fx & portfolio adj.) to EUR 8,025 million / EBITDA before special items up by 4.1 percent to EUR 2,204 million / Sales and earnings growth at Pharmaceuticals / Consumer Health business weak, as expected / Sales gains at Crop Science and Animal Health / Net income of EUR 3,881 million including Covestro book profit / Core earnings per share at EUR 1.47 (minus 3.9 percent) / Group outlook for 2017 confirmed based on change in structure more
Tuesday - September 19, 2017 Crop Science Division of Bayer well positioned to fulfill future customer, market and societal needs Global seed and crop protection market will continue to grow / Business in Brazil expected to return to normal in 2018 / Progress being made in planned Monsanto acquisition / Anticipated closing in early 2018 / Planned R&D investment of approximately EUR 1 billion in 2017 / R&D efforts to bring 15 new products to farmers between 2017 and 2020 / Strong focus on innovation and sustainability / Commitment to transparency more
Monday - June 12, 2017 Bayer fundraisers take part in Bayer Spin for LauraLynn The team at Bayer launched an ambitious fundraising activity to support their charity of the year for 2017, LauraLynn Ireland’s Children’s Hospice. Employees undertook a 500km cycle across three countries which theynamed ‘Bayer Spin for LauraLynn’. more
Tuesday - July 19, 2016 Bayer and White Ribbon Alliance Announce Self-Care Policy Recommendations and Programs to Support Maternal, Newborn and Child Health Joint white paper, released at United Nations High Level Political Forum, outlines key policy changes to address self-care barriers at the global, national and local level / Bayer commits $1.3M in programs and services; three-year commitment to help women and children in developing countries more
Thursday - February 25, 2016 Another record year for Bayer Focus on the Life Sciences following the successful stock market flotation of Covestro / Substantial sales and earnings increases at HealthCare / Good business development at CropScience despite a weaker market environment / Covestro posts strong earnings improvement / Group sales increase to EUR 46,324 million (plus 12.1 percent / Fx & portfolio adj. plus 2.7 percent) more
